BTIG Research Forecasts Strong Price Appreciation for Stryker (NYSE:SYK) Stock

Stryker logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • BTIG Research raised its Stryker price target to $345 from $304 and maintained a Buy rating, implying 8.76% upside from the current share price.
  • Analyst sentiment is broadly positive: 21 analysts rate the stock Buy and seven Hold, for a consensus Moderate Buy rating and average price target of $343.77.
  • Stryker’s latest quarterly results fell short of estimates, with EPS of $3.52 versus $3.55 expected and revenue of $6.52 billion versus $6.62 billion; revenue nevertheless grew 7.6% year over year.
  • MarketBeat previews top five stocks to own in December.

Stryker (NYSE:SYK - Get Free Report) had its target price upped by equities research analysts at BTIG Research from $304.00 to $345.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a "buy" rating on the medical technology company's stock. BTIG Research's price objective would suggest a potential upside of 8.76% from the company's current price.

Other equities analysts also recently issued research reports about the company. Stifel Nicolaus dropped their price target on Stryker from $330.00 to $325.00 and set a "buy" rating on the stock in a research report on Monday, November 2nd. Canaccord Genuity Group downgraded Stryker from a "buy" rating to a "hold" rating and decreased their price objective for the company from $385.00 to $300.00 in a report on Friday, October 30th. Raymond James Financial reaffirmed an "outperform" rating and issued a $323.00 price objective (down from $370.00) on shares of Stryker in a research note on Friday, October 30th. Piper Sandler raised their target price on shares of Stryker from $325.00 to $350.00 and gave the company an "overweight" rating in a research report on Monday, November 9th. Finally, Jefferies Financial Group reduced their price target on shares of Stryker from $440.00 to $405.00 and set a "buy" rating for the company in a report on Tuesday, September 22nd. Twenty-one research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $343.77.

Get Our Latest Analysis on SYK

Stryker Stock Performance

Shares of NYSE:SYK opened at $317.20 on Wednesday. The firm's 50 day simple moving average is $293.26 and its 200-day simple moving average is $322.17. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 2.18. Stryker has a one year low of $267.00 and a one year high of $389.33. The firm has a market cap of $120.76 billion, a PE ratio of 33.78, a price-to-earnings-growth ratio of 2.13 and a beta of 0.78.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.74%. The firm had revenue of $6.52 billion during the quarter, compared to analysts' expectations of $6.62 billion. During the same quarter in the previous year, the firm posted $3.19 EPS. The firm's revenue for the quarter was up 7.6% on a year-over-year basis. As a group, equities analysts predict that Stryker will post 14.85 EPS for the current year.

Insiders Place Their Bets

In related news, insider Dylan Crotty sold 441 shares of the firm's stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider owned 6,102 shares of the company's stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda Stryker sold 550,000 shares of Stryker stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $325.32, for a total value of $178,926,000.00. Following the completion of the transaction, the director owned 1,701,375 shares in the company, valued at $553,491,315. This trade represents a 24.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 4.60% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Gables Capital Management Inc. acquired a new stake in Stryker in the second quarter valued at approximately $25,000. Kilter Group LLC acquired a new position in shares of Stryker during the second quarter worth $25,000. Cornerstone Financial Management LLC lifted its holdings in shares of Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company's stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Highland Investment Advisors LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at $25,000. Finally, Compass Financial Management LLC acquired a new stake in shares of Stryker in the 2nd quarter worth $27,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

About Stryker

(Get Free Report)

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company's products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Read More

Analyst Recommendations for Stryker (NYSE:SYK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Stryker Right Now?

Before you consider Stryker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.

While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines